Table of contents


On 3 March 2005, orphan designation (EU/3/05/263) was granted by the European Commission to AOP Orphan Pharmaceuticals AG, Austria, for dimethyl sulfoxide for the treatment of severe closed traumatic brain injury.

Key facts

Active substance
Dimethyl sulfoxide
Disease / condition
Treatment of severe closed traumatic brain injury
Date of first decision
EU designation number

Sponsor's contact details

AOP Orphan Pharmaceuticals AG
Wilheminenstrasse 91/II/f/5
1160 Wien, Austria
Telephone: +43 1 50 33 72 44
Telefax: +43 1 50 37 24 45

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating